Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

Article regarding R’s effectiveness (or lack of) to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
tikotiko Member Profile
 
Followed By 17
Posts 2,075
Boards Moderated 0
Alias Born 10/09/17
160x600 placeholder
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates & Durable Clinical Benefit in a Pivotal Indolent No... Business Wire - 12/5/2020 12:30:00 PM
New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma Business Wire - 12/5/2020 10:00:00 AM
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial Business Wire - 12/5/2020 10:00:00 AM
Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-exposure Prophy... PR Newswire (Canada) - 12/1/2020 7:00:00 AM
Gilead Canada a reçu un avis de conformité pour DESCOVY® (emtricitabine, ténofovir alafénamide) pour la prophylaxie pré... PR Newswire (Canada) - 12/1/2020 7:00:00 AM
Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 Business Wire - 11/23/2020 7:00:00 PM
Pfizer, Gilead, Ross: What to Watch When the Stock Market Opens Today Dow Jones News - 11/20/2020 9:31:00 AM
Pfizer, Gilead, Ross: What to Watch When the Stock Market Opens Today Dow Jones News - 11/20/2020 8:30:00 AM
Pfizer, Gilead, Ross: What to Watch When the Stock Market Opens Today Dow Jones News - 11/20/2020 7:32:00 AM
WHO Recommends Against Use of Gilead Covid-19 Drug Remdesivir -- Update Dow Jones News - 11/19/2020 7:54:00 PM
WHO Recommends Against Use of Gilead Covid-19 Drug Remdesivir Dow Jones News - 11/19/2020 7:40:00 PM
Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Stud... Business Wire - 11/18/2020 8:35:00 AM
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH Business Wire - 11/15/2020 5:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/12/2020 5:51:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/12/2020 5:45:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/12/2020 5:35:15 PM
Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020 Business Wire - 11/5/2020 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2020 6:05:34 AM
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis Business Wire - 11/2/2020 4:01:00 PM
Gilead Quarterly Revenue Rises on Remdesivir Sales -- Update Dow Jones News - 10/28/2020 7:33:00 PM
Gilead Quarterly Revenue Rises on Remdesivir Sales Dow Jones News - 10/28/2020 5:40:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2020 4:11:05 PM
Gilead Sciences Announces Fourth Quarter 2020 Dividend Business Wire - 10/28/2020 4:02:00 PM
Gilead Sciences Announces Third Quarter 2020 Financial Results Business Wire - 10/28/2020 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/26/2020 7:13:19 PM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences